DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.22
-0.10 (-1.58%)
At close: Apr 28, 2026, 4:00 PM EDT
6.22
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT

DiaMedica Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Selling, General & Admin
9.787.628.166.164.88
Upgrade
Research & Development
24.6119.0613.117.848.77
Upgrade
Operating Expenses
34.426.6821.271413.65
Upgrade
Operating Income
-34.4-26.68-21.27-14-13.65
Upgrade
Interest & Investment Income
1.662.271.930.35-
Upgrade
Other Non Operating Income (Expenses)
----0.08
Upgrade
EBT Excluding Unusual Items
-32.74-24.41-19.34-13.65-13.56
Upgrade
Pretax Income
-32.74-24.41-19.34-13.65-13.56
Upgrade
Income Tax Expense
0.030.030.040.030.03
Upgrade
Net Income
-32.77-24.44-19.38-13.68-13.59
Upgrade
Net Income to Common
-32.77-24.44-19.38-13.68-13.59
Upgrade
Shares Outstanding (Basic)
4740332621
Upgrade
Shares Outstanding (Diluted)
4740332621
Upgrade
Shares Change (YoY)
16.28%24.07%23.16%27.29%32.48%
Upgrade
EPS (Basic)
-0.70-0.60-0.60-0.52-0.65
Upgrade
EPS (Diluted)
-0.70-0.60-0.60-0.52-0.65
Upgrade
Free Cash Flow
-29.1-22.1-18.75-11.59-12.27
Upgrade
Free Cash Flow Per Share
-0.62-0.55-0.58-0.44-0.59
Upgrade
EBITDA
-34.35-26.64-21.24-13.98-13.62
Upgrade
D&A For EBITDA
0.040.040.030.030.02
Upgrade
EBIT
-34.4-26.68-21.27-14-13.65
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.